HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition

Effective experimental prophylactic vaccines against viral pathogens such as herpes simplex virus type 1 (HSV-1) have been shown to protect the host through T and/or B lymphocyte-driven responses. Previously, we found a live-attenuated HSV-1 mutant, 0ΔNLS used as a prophylactic vaccine, provided sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Gmyrek, Grzegorz B., Berube, Amanda N., Sjoelund, Virginie H., Carr, Daniel J. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508094/
https://www.ncbi.nlm.nih.gov/pubmed/36151255
http://dx.doi.org/10.1038/s41598-022-20180-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508094/
https://www.ncbi.nlm.nih.gov/pubmed/36151255
http://dx.doi.org/10.1038/s41598-022-20180-0

Ejemplares similares